by Medicine by Design | May 13, 2024
CCRM, the publisher of Signals, has enhanced its long-standing relationship with the University of Toronto’s Medicine by Design through a new strategic alliance. This profile is one in a series of profiles that feature “people” of Medicine by Design. Some minor edits...
by Medicine by Design | Apr 29, 2024
CCRM, the publisher of Signals, has enhanced its long-standing relationship with the University of Toronto’s Medicine by Design through a new strategic alliance. This profile is one in a series of profiles that feature “people” of Medicine by Design. Some minor edits...
by Stacey Johnson | Feb 23, 2024
As a fair-skinned, freckled person (my mom says she painted them on me while I slept), and one who has a family history of skin cancers and melanoma, the news on February 19 that Iovance Biotherapeutics’ AMTAGVITM received U.S. Food and Drug Administration (FDA)...
by Tyler Wenzel | Dec 21, 2023
I can recall the first time that I heard about the idea of gene therapy. It was over 20 years ago, and possibly like many students in school, I was assigned to write an essay on the ethical considerations for allowing or disallowing gene editing on humans. I remember...
by Tyler Wenzel | Nov 23, 2023
Cell therapies that replenish a healthy cell niche have long been an attractive approach to treat a variety of diseases, such as Parkinson’s disease, which are incurable and characterized by the loss of critical cell functions. The attractiveness of cell therapies is...
by Kevin Robb | Nov 9, 2023
BlueRock Therapeutics has generated considerable media buzz with their announcement of positive Phase I clinical trial data on bemdaneprocel (BRT-DA01), an investigational, stem cell-derived, dopaminergic therapy for Parkinson’s disease. The trial is the result of...
Comments